

Jubilant Life Sciences Ltd
 Regd. Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar-244 223 (U.P.)
 Statement of Unaudited Results for the Quarter ended 30th June,2012

(₹ in Lacs)

STAND ALONE RESULTS				Particulars	CONSOLIDATED RESULTS			
Quarter Ended		Year Ended			Quarter Ended		Year Ended	
June 30	March 31	June 30	March 31		June 30	March 31	June 30	March 31
(Unaudited)	(Audited)	(Unaudited)	(Audited)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
2012	2012	2011	2012		2012	2012	2011	2012
				PART I				
				Income from operations				
73682	69356	61490	261764	(a) Net sales/income from operations (Net of excise duty)	123589	117110	94187	425395
575	723	476	2343	(b) Other Operating Income	441	3319	845	4918
74257	70079	61966	264107	Total Income from operations (net)	124030	120429	95032	430313
65813	67773	52296	236145	Expenses	102570	102675	81241	364604
35361	31919	28455	123995	a) Cost of materials consumed	43278	38094	33578	149469
4727	5287	5706	24368	b) Purchase of traded goods	7593	9233	6787	32327
(1718)	546	(2217)	(9326)	c) Change in inventories of finished goods, work-in-progress and traded goods	(3609)	(825)	(4201)	(20009)
8369	8719	5544	26976	d) Power & fuel	8599	8304	6001	27876
5608	5349	4678	20723	e) Employee benefits expense	23143	21241	18976	83637
3607	4283	2768	13200	f) Depreciation and amortization expenses	5906	6619	4977	22065
9859	11670	7362	36209	g) Other expenses	17660	20009	15123	69239
8444	2306	9670	27962	Profit/(loss) from operations before other income, finance cost and exceptional items	21460	17754	13791	65709
174	241	235	894	Other Income	308	471	244	1529
8618	2547	9905	28856	Profit/(loss) from ordinary activities before finance costs & exceptional items	21768	18225	14035	67238
4505	4552	3003	15442	Finance costs	5934	5855	4362	20959
4113	(2005)	6902	13414	Profit/(loss) from ordinary activities after finance costs but before exceptional items	15834	12370	9673	46279
10424	(1742)	268	18008	Exceptional items	10424	14641	418	34868
(6311)	(263)	6634	(4594)	Profit/(loss) from ordinary activities before tax	5410	(2271)	9255	11411
1049	15	1245	3497	Tax expense (Net)	3887	3508	1516	6842
(7360)	(278)	5389	(8091)	Net profit/(loss) from ordinary activities after tax	1523	(5779)	7739	4569
-	-	-	-	Extraordinary items (net of tax expenses)	-	-	-	-
(7360)	(278)	5389	(8091)	Net profit/(loss) for the period	1523	(5779)	7739	4569
-	-	-	-	Share of Profit/(loss) of Associate Company	-	-	-	-
-	-	-	-	Minority Interest	1022	574	27	3113
(7360)	(278)	5389	(8091)	Net profit/(loss) after taxes, minority interest and share of profit/loss of associates	501	(6353)	7712	1456
1593	1593	1593	1593	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593
			197391	Reserves (excluding revaluation reserve)				231384
(4.62)	(0.17)	3.38	(5.08)	Earnings per share before and after extraordinary items (Not annualized)				
(4.62)	(0.17)	3.38	(5.08)	Basic (₹)	0.31	(3.99)	4.84	0.91
				Diluted (₹)	0.31	(3.99)	4.84	0.91
				PART II				
				PARTICULARS OF SHAREHOLDING				
				Public shareholding				
81166083	81166083	84129115	81166083	- Number of shares (₹ 1 each)	81166083	81166083	84129115	81166083
50.96	50.96	52.82	50.96	- Percentage of shareholding	50.96	50.96	52.82	50.96
				Promoters and promoter group Shareholding				
				a) Pledged/Encumbered				
3374000	3374000	7887333	3374000	- Number of shares	3374000	3374000	7887333	3374000
4.32	4.32	10.50	4.32	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	4.32	4.32	10.50	4.32
2.12	2.12	4.95	2.12	- Percentage of shares (as a % of the total share capital of the company)	2.12	2.12	4.95	2.12
				b) Non-Encumbered				
74741056	74741056	67264691	74741056	- Number of shares	74741056	74741056	67264691	74741056
95.68	95.68	89.50	95.68	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	95.68	95.68	89.50	95.68
46.92	46.92	42.23	46.92	- Percentage of shares (as a % of the total share capital of the company)	46.92	46.92	42.23	46.92
				Investor Complaints				
				Pending at the beginning of the quarter	Nil			
				Received during the quarter	4			
				Disposed of during the quarter	4			
				Remaining unresolved at the end of the quarter	Nil			

2

Notes:

1. In order to provide better understanding of nature of business lines and operating matrix the Company has identified two reportable segment as i) Pharmaceuticals and ii) Life Sciences Ingredients effective current quarter. The Pharmaceutical Segment comprises of Active Pharmaceutical Ingredients, Generics, Speciality Pharma, Contract Manufacturing of Sterile and Non Sterile Products, Drug Discovery and Development Solutions and Healthcare business and Life Sciences Ingredients Segment comprises of Proprietary Products and Exclusive Synthesis, Nutrition Ingredients and Life Sciences Chemical business.

2. The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 "The Effects of Changes in Foreign Exchange Rates". Accordingly exchange differences amounting to ₹ 1678 lacs has been amortized during the quarter and the accumulated debit balance in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) is ₹ 13435 lacs as at 30th June, to be amortized over the balance life of the respective loan and ₹ 2367 lacs has been debited to Capital Work in Progress.

3. The company has applied hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered accountants of India and the debit balance in hedge reserve as at 30th June, 2012 is ₹ 8379 lacs (Consolidated ₹ 9112 lacs).

4. Exceptional items include :

i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 1678 lacs (Consolidated ₹ 1678 lacs) for Q1-FY 2013.

ii) Mark to Market in respect of Currency & Interest rate swap contracts at the quarter end resulting in loss/(gain) amounting to ₹ 8746 lacs (Consolidated ₹ 8746 lacs) for Q1 FY 2013.

5. Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement.

6. Previous year / periods figures have been regrouped/reclassified wherever necessary.

7. The above un-audited results were, subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 23rd July, 2012.

Place : Noida

Dated : 23rd July, 2012

For Jubilant Life Sciences Ltd.



Shyam S Bhartia
Chairman & Managing Director

Jubilant Life Sciences Ltd.

(under Clause 41 of the Listing Agreement)

Statement of Unaudited Results for the Quarter ended 30th June,2012

(₹ in Lacs)

STAND ALONE RESULTS				Particulars	CONSOLIDATED RESULTS			
Quarter Ended			Year Ended		Quarter Ended			Year Ended
June 30	March 31	June 30	March 31		June 30	March 31	June 30	March 31
(Unaudited)	(Audited)	(Unaudited)	(Audited)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
2012	2012	2011	2012		2012	2012	2011	2012
				Segment revenue				
17241	16776	11305	56811	a. Pharmaceuticals	64124	64626	44148	220131
57084	53361	50756	207602	b. Life Sciences Ingredients	59974	55861	50979	210488
74325	70137	62061	264413	Total	124098	120487	95127	430619
68	58	95	306	Less : Inter segment revenue	68	58	95	306
74257	70079	61966	264107	Net sales/Income from operations	124030	120429	95032	430313
				Segment results (profit+)/loss(-) before tax and interest from each segment				
17241	16776	11305	56811	a. Pharmaceuticals	64124	64626	44148	220131
57016	53303	50661	207296	b. Life Sciences Ingredients	59906	55803	50884	210182
74257	70079	61966	264107	Total	124030	120429	95032	430313
4313	2665	1184	10032	a. Pharmaceuticals	16431	17192	5193	47088
7862	1381	10205	25612	b. Life Sciences Ingredients	8760	2301	10339	26302
12175	4046	11389	35644	Total	25191	19493	15532	73390
4505	4552	3003	15442	Less : i Interest(Finance costs)	5934	5855	4362	20959
14155	(2)	1987	25690	ii. Other un-allocable expenditure(including exceptional items)	14155	16380	2159	42549
(174)	(241)	(235)	(894)	iii. Un-allocable Income(including exceptional items)	(308)	(471)	(244)	(1529)
(6311)	(263)	6634	(4594)	Total profit/(loss) before tax	5410	(2271)	9255	11411
				Capital Employed (Segment assets less Segment liabilities)				
94961	90475	84372	90475	a. Pharmaceuticals	450398	417359	386038	417359
167253	162059	161571	162059	b. Life Sciences Ingredients	183674	174624	172325	174624
262214	252534	245943	252534	Total capital employed in segments	634072	591983	558363	591983
245702	261221	232696	261221	Add: Un-allocable corporate assets less liabilities	35955	51154	25823	51154
507916	513755	478639	513755	Total capital employed in the Company	670027	643137	584186	643137

